Review Article

Current State of Vascular Resections in Pancreatic Cancer Surgery

Thilo Hackert, Lutz Schneider, and Markus W. Büchler

Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany

Correspondence should be addressed to Thilo Hackert; thilo_hackert@med.uni-heidelberg.de

Received 24 November 2014; Accepted 5 March 2015

Academic Editor: Dejan Radenkovic

Copyright © 2015 Thilo Hackert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pancreatic cancer (PDAC) is the fourth leading cause of cancer-related mortality in the Western world and, even in 2014, a therapeutic challenge. The only chance for long-term survival is radical surgical resection followed by adjuvant chemotherapy which can be performed in about 20% of all PDAC patients by the time of diagnosis. As pancreatic surgery has significantly changed during the past years, extended operations, including vascular resections, have become more frequently performed in specialized centres and the border of resectability has been pushed forward to achieve a potentially curative approach in the respective patients in combination with neoadjuvant and adjuvant treatment strategies. In contrast to adjuvant treatment which has to be regarded as a cornerstone to achieve long-term survival after resection, neoadjuvant treatment strategies for locally advanced findings are currently under debate. This overview summarizes the possibilities and evidence of vascular, namely, venous and arterial, resections in PDAC surgery.

1. Introduction

Overall long-term survival rates of 1–5% are associated with pancreatic cancer (PDAC) underlining the poor prognosis of this tumor entity [1, 2]. The major obstacle to improve this situation is the fact that PDAC diagnosis is made late and in an advanced tumor stage in the majority of patients precluding them from surgical resection due to distant spread of the disease. Approximately 10–20% of PDAC patients can consequently undergo potentially curative surgery aiming at a radical R0 resection which results in long-term 5-year survival rates of 20–25% [3, 4]. As pancreatic surgery is challenging with regard to preoperative diagnostic, surgical procedures as well as postoperative care and complication management, the value of centralization of pancreatic surgery in centres of excellence and high volume institutions is unquestionable today and has been demonstrated in numerous studies the last 15 years [5, 6]. In this setting, implying experience of the individual surgeon who continuously performs pancreatic resections and the environment with an interdisciplinary team of specialists to optimize perioperative care including ICU treatment and complication management, mortality rates following major pancreatic resections

below 5% are standard today [5, 6]. In this context, the borders of resectability have been pushed and extended surgical approaches in PDAC have become commonly performed, which include vascular as well as multivisceral resections [7, 8]. This has been accompanied by scientific work-up of the results of these operations in terms of surgical as well as oncological outcome resulting in an increasing number of publications and a meanwhile satisfying level of evidence with a relevant influence on recent national and international guidelines consensus statements [9, 10]. The present review gives an overview on the development and current state of venous and arterial resections in PDAC surgery.

2. Evaluation of Resectability and Borderline Resectability

Situations in which vascular resections are required are often described as “borderline resectable” findings. In 2014, the International Study Group for Pancreatic Surgery (ISGPS) has published a consensus statement to standardize the definition of borderline resectability in accordance with the guidelines of the National Comprehensive Cancer Network

FIGURE 1: CT scan (coronary reconstruction) showing PDAC tumor infiltration of the portal vein confluence (white circle). Superior mesenteric vein (black arrow), portal vein (broken black arrow), and splenic vein (white arrow) without thrombosis, adequate diameter of the portal, and superior mesenteric vein to perform an end-to-end anastomosis.

(NCCN) as well as the definition of extended resections [11, 12]. Following these recommendations, preoperative evaluation of resectability should be based on a computed tomography (CT) scan with a pancreas-specific protocol, for example, a “hydropancreas” CT, as this offers best local resolution with regard to tumor extension and infiltration towards the vascular structures (Figure 1). Three grades of resectability can be defined for localized PDAC which are termed as “resectable,” “borderline resectable,” and “irresectable” [11]. While a resectable tumor has no vascular attachment (no distortion of the venous structures and clearly preserved fat planes towards the arteries), borderline resectability is defined as distortion/narrowing/occlusion of the mesentericoportal veins with a technical possibility of reconstruction on the proximal and distal margin of the veins. Furthermore, a semicircumferential abutment ($\leq 180^\circ$) of the superior mesenteric artery (SMA) or an attachment at the hepatic artery without the celiac axis is regarded as a borderline resectable finding. Consequently, irresectability is defined as a more extended involvement of the SMA, the celiac axis, aorta or inferior vena cava. Furthermore, involvement of the mesentericoportal venous system can fulfill the criteria of irresectability if there is no technical possibility for reconstruction, for example, in case of tumor-associated portal cavernous transformation.

Regarding the performance of resections, borderline findings in venous and arterial vessel involvement have to be differentiated. In venous borderline resectability, no neoadjuvant treatment is recommended, instead upfront surgery should be performed and, if the intraoperative finding matches the presumed borderline situation as defined above, completed as an en bloc tumor removal with venous replacement [11, 12]. In contrast, when suspected arterial borderline resectability is intraoperatively confirmed as a true arterial involvement, no general recommendation for resection is given, but palliative treatment should be regarded as the standard of care. In individual decision, however, these recommendations may be modified and neoadjuvant treatment with a consecutive reexploration and eventually

resection is possible as well as direct arterial resection in exceptional cases or under study conditions.

Restaging after neoadjuvant treatment may be challenging, as the differentiation of vital tumor and fibrosis by conventional cross-sectional imaging is limited and even PET-CT scans do not offer 100% accuracy [27]. Therefore, in cases of clear tumor regression, a surgical exploration should be performed as well as in patients showing stable disease status after completion of the neoadjuvant treatment. The rationale for this is the fact that, despite still visible soft tissue, this is often found to be only fibrotic residual changes [28]. In these cases, after confirming absence of vital tumor, a sharp dissection without vascular resection is possible and eventually a ypT0 situation may be found. Patients with a clear tumor progression under neoadjuvant treatment should be excluded from secondary exploration. Due to the three scenarios described, the neoadjuvant treatment is helpful to stratify patients and recognize those with borderline findings who do not benefit from extended resections.

3. Venous Resections

En bloc vascular resections during pancreatoduodenectomy (PD) to achieve tumor clearance and improve survival in case of portomesenteric vein involvement were published more than 30 years ago [29]. From these anecdotal reports, the technical feasibility was concluded; however, it took another two decades until these approaches gained widespread acceptance in centres around the world. Besides venous resection in PD, this approach is also performed during distal (DP) or total pancreatectomy (TP) [30–32]. However, especially in TP, several aspects regarding venous drainage of the stomach have to be respected when the portal, and usually also the splenic vein, is resected, which is mentioned in detail below.

The site of tumor infiltration of the vein has to be carefully evaluated already in the preoperative cross-sectional imaging. Proximal tumor adherence or infiltration can usually be handled more easily, as the vessel diameter is large enough to create a sufficient anastomosis. In case of a more distally located tumor infiltration far below the mesenterico-splenic confluence, the decreasing vascular diameter of the superior mesenteric vein may limit the technical possibility to perform a venous resection [11].

Regarding surgical technique, venous resections can be performed differently depending on the location and length of tumor adherence. A latero-tangential resection of the portal vein is possible when tumor infiltration reaches the vein from the right circumference and can be excised with a small patch and direct closure of the defect directly without a hemodynamically relevant stenosis [30–32]. Adequate venous drainage of the small bowel needs to be ensured afterwards by direct flow measurement and the clinical evaluation of the perfusion aspect of the intestine during the remaining operation time, which is usually long enough to recognize venous congestion if present.

When a tangential vein resection is not possible, the mesenteric root should be mobilized completely by resolving the attachment of the right hemicolon to the retroperitoneal adhesions [33]. This gives a great flexibility of the mesenteric

vein and almost always allows approximation of the distal and proximal resection margins of the vein without any critical tension. Following resection of the tumor-bearing venous segment, continuity of the vessel can be restored by a direct end-to-end anastomosis as the corresponding diameters of the distal and proximal lumen can usually be adapted without causing any obstruction to the free venous bowel drainage.

In case the resected venous length cannot be bridged by the direct anastomosis, a vascular graft needs to be inserted. For this purpose, autologous grafting (e.g., renal vein and saphenous vein) is possible but requires a venous harvesting before clamping and resection [34]. Alternatively, synthetic grafts, for example, a ringed goretex prosthesis, can be chosen to bridge the resected vein segment. The insertion of a synthetic graft always implies the possible problems artificial material may cause in case of infection or anastomotic leakage. A situation of a synthetic graft in combination with a pancreatic fistula must be regarded as a high risk constellation for postpancreatectomy hemorrhage or difficult to treat long-lasting graft infection. Yet, the clinical impact of this complication seems to be rather small; in a series of 110 patients undergoing venous resection with different reconstruction techniques no difference in surgical outcome was shown when different types of venous reconstruction (venorrhaphy, end-to-end anastomosis, and graft insertion) were observed [33].

When other surgical outcome parameters are considered, it has been demonstrated that both, resection with a direct anastomosis or the interposition of a graft, can be performed safely. Large series showed that surgical morbidity and mortality rates are comparable to standard pancreatic head resections [33–35]. This has been scientifically examined and confirmed in two recently published systematic reviews [36, 37]. In the review by Siriwardana and Siriwardana [36], 52 manuscripts with 6333 patients in whom pancreatic resection was performed for PDAC were included. 1646 of these patients (26%) underwent synchronous porto-superior mesenteric vein resection mainly together with partial pancreateoduodenectomy (71%) or total pancreatectomy (24%). Median operation time was 8.5 hours, median blood loss 1750 mL, overall morbidity 42% (9 to 78%), and perioperative mortality 5.9%. The more recent meta-analysis by Zhou et al. [37] included 19 studies and 661 patients with venous resections during PDAC resections that were compared to 2247 patients undergoing similar operation without vessel resection. Both groups were characterized by comparable surgical outcome. Furthermore, in terms of oncological results, no difference in overall survival between both patient collectives was found, resulting in a 5-year survival rate of 12.3%, certainly superior to palliative treatment. Table 1 gives an overview of the largest studies on venous resections in PDAC.

A special aspect in venous resections that has to be respected in certain situations is the patency of venous gastric drainage. In PD, the splenic vein can be closed during venous resection as the stomach is usually drained sufficiently via the coronary vein (if preserved) and collaterals via the short gastric veins.

In contrast, in TP for PDAC, which is usually combined with splenectomy, venous resections may cause severe

disturbances of the gastric drainage, especially when the coronary vein is removed during resection. In this situation, two scenarios may occur. On one hand a venous congestion of the remaining stomach may require a classical distal or even subtotal stomach resection to avoid ischemic complications with either long-lasting delayed gastric emptying or even necrosis of the stomach with the need for a reintervention and consecutive stomach resection. On the other hand, if the resected coronary vein can technically be preserved, there is the possibility for reinsertion into the mesentericoportal axis to restore stomach drainage and avoid any type of gastrectomy [38].

In addition to PD and venous resection alone, also multivisceral approaches established procedures to achieve a radical tumor removal [24, 31, 32]. Although these are associated with an increased morbidity, perioperative mortality and long-term survival are not negatively influenced in these patients [31, 32]. In approximately 20% of the patients, multivisceral resection is performed together with portal or superior mesenteric vein resections. This additional procedure does not increase the risk for complications and should therefore be performed in patients qualifying for an extended approach of complete tumor removal [24].

In conclusion, venous resections during surgery for pancreatic cancer can therefore be regarded as a standard procedure in experienced hands and should be performed in a routine setting to achieve a complete removal of the tumor, which has meanwhile been generally accepted and is explicitly stated in national and international guidelines such as the German and the ISGPS consensus statements [9, 10].

4. Arterial Resections

The resection of the celiac axis or the superior mesenteric artery has occasionally been performed since the 1970s in selected patients but is still regarded as an extraordinary approach in PDAC surgery [31, 32, 39–42]. Arterial tumor infiltration of the hepatic artery, celiac axis, or the superior mesenteric artery can be regarded as a symptom of biologically aggressive tumor spread. Although in some patients this is considered as borderline resectable according to the ISGPS consensus statement, an upfront resection is rarely recommendable, even if it can technically be performed [10]. In general, in case of arterial tumor infiltration, a neoadjuvant treatment should be evaluated to achieve a better local tumor control. This treatment can be performed following different study protocols and is not standardized yet. In many protocols, gemcitabine is combined with a 50–60 Gy radiation over a 6-week period, followed by 4–6 week interval to await downsizing and development of fibrosis as a consequence of the therapy [43]. After restaging, patients should be subjected to surgical exploration as long as no signs of systemic tumor spread are visible. Using this approach, in 33–50% of all primarily irresectable patients, a radical resection is possible which achieves R0 resection rates comparable to standard resections [44–47]. To clarify arterial infiltration along the superior mesenteric artery intraoperatively, the “artery-first” approach is a useful procedure [48]. Preparation starts at the superior mesenteric artery as the initial step before

TABLE 1: Series with >50 patients comparing resection for pancreatic cancer with and without mesentericoportal vein resections 1995–2015.

Author, year	Patients PVR/no PVR	OP time (min)	R0 rate (%)	Morbidity (%)	Mortality (%)	Survival (months)
Harrison et al., 1996 [13]	58/274	444/348	74.1/76.3	nm	5.0/3.0	13.0/17.0 (median)
Hartel et al., 2002 [14]	68/203		61.8/73.4	27.0/22.0	4.0/3.0	
Riediger et al., 2006 [15]	53/169	500/440	69.0/79.0	23.0/35.0	3.8/4.1	15.0% (5 years)
Ouaissi et al., 2010 [16]	59/82	480/420	57.6/86.6	52.5/54.9	1.7/1.2	17.5/18.7 (median)
Banz et al., 2012 [17]	51/275	nm	49.0/63.3	27.5/28.4	13.7/5.1	14.5/14.8 (median)
Murakami et al., 2013 [18]	61/64	nm	50.8/71.9	36.1/21.9	0.0/0.0	14.7/26.7 (median)
Ravikumar et al., 2014 [19]	230/840	300/250	37.1/48.4	34.3/30.8	4.6/4.2	18.2/18.0 (median)
Kulemann et al., 2015 [20]	131/208	463/427	64.6/76.2	55.7/50.0	3.3/5.1	21.6/19.7 (median)

nm: not mentioned.

TABLE 2: Series of arterial resections for pancreatic cancer.

Author, year	Patients	OP time (min)	R0 rate (%)	Morbidity (%)	Mortality (%)	Survival (months)
Stitzenberg et al., 2008 [21]	12	660	50.0	100.0	17.0	17
Wang et al., 2008 [22]	19	nm	nm	36.8	0.0	16.0% (1 year)
Sugiura et al., 2009 [23]	26	nm	nm	nm	nm	10% (5 years)
Hartwig et al., 2009 [24]	14	450	57.4	37.6	6.9	nm
Ouaissi et al., 2010 [16]	8	570	50.0	75.0	12.5	11.0 (median)
Yamamoto et al., 2012 [25]	13	620	31.0	92.0	0.0	20.8 (median)
Yoshidome et al., 2014 [26]	7	522	nm	29.0	0.0	12.7 (median)

nm: not mentioned.

further mobilization of the pancreatic head. The preparation is carried out with the incision of the peritoneal layer at the ligament of Treitz from the left side and continued by clearing the tissue along the artery down to the origin from the aorta via this access. Tumor infiltration can be ruled out or confirmed by this preparation to determine the further procedure.

In a recent review, the role of arterial resection has been critically evaluated [49]. Besides this left-sided inframesocolic “artery-first” approach, various other techniques have been published starting from arterial preparation on the right side or from a supracolic approach [50–54]. Regarding resection of the superior mesenteric artery, only five studies were available, including a total number of less than 30 patients. All authors showed that the resection is technically possible; grafting with the saphenous vein was the most commonly used method for reconstruction. However, morbidity of this approach is high and the oncological outcome is not yet convincing from the limited evidence.

Celiac axis or hepatic artery resection is performed more often. The available literature on this topic includes approximately 200 patients [55, 56]. Surgical morbidity is up to 40%; mortality in pancreaticoduodenectomy with arterial resection ranges from 0 to 35%, showing the inconsistent data basis of this approach. Outcome in terms of oncological results seems to justify the approach especially in distal pancreatectomy [57] as long-term survival seems to be nearly equal to the standard approaches. However, it must be clearly stated that arterial resection does not represent a standard procedure but has to be based on an individual decision of an experienced pancreatic surgeon. Table 2 summarizes selected studies on arterial resections.

From the technical point of view, when arterial resection is performed, resection without reconstruction has to be differentiated from resection with direct anastomosis or graft insertion to replace the resected vessel. The celiac axis might be resected down to its aortal orifice in PD as well as in DP or TP [55–57]. As long as the proper hepatic artery can be

FIGURE 2: Intraoperative view in combined arterial and venous resection. Arterial anastomosis after resection of a replaced right liver artery (black arrow) infiltrated by the resected PDAC. Portal vein anastomosis (broken black arrow) and pancreatic remnant (white arrow) before completing the pancreatojejunostomy.

preserved, a reconstruction is possible. The left gastric and splenic artery can usually be cut without reconstruction; a consecutive splenectomy may be necessary in some patients. Restoration of the hepatic perfusion must be ensured by reconstruction of the proper or common hepatic artery. This reconstruction can be done with an interposition of any arterial vessel of the celiac axis or a venous interposition graft. The splenic artery especially is a suitable vessel for this reconstruction, either with a transposition if the base of celiac axis can be preserved or with an interposition which requires an additional anastomosis between graft and aorta [58].

However, the arterial perfusion of the liver should be controlled by regular duplex examinations and restored aggressively in case of a vessel occlusion. Arterial hepatic perfusion failure may otherwise cause acute problems postoperatively in terms of liver ischemia, necrosis, and infection and is a risk factor for bile-duct associated complications in the long-term follow-up [59, 60]. Using this approach, arterial resection can be carried out safely in experienced hands but has to be regarded as a highly individual decision in suitable patients.

5. Combined Vascular Resections

A combination of both venous and arterial vessel resections is technically possible in selected patients. Comparable to arterial resections alone, this approach is not recommended as a standard procedure but has to be based on individual decisions. As it has been performed in only small patient series to date, there is only very limited literature published on this topic; no conclusive evidence with regard to perioperative morbidity and oncological outcome is available. Combined vascular resections may be an individual option for patients that are considered suitable in terms of age and comorbidities (Figure 2). As this approach may be associated with a considerable surgical morbidity and even mortality as well as impaired postoperative quality of life compared to standard pancreatic operations, it must not only be evaluated with focus on technical feasibility but also on quality-adjusted lifetime that may be gained by its performance. As these extensive resections may be performed during total or even multivisceral pancreatectomies, side-effects of these approaches may be aggravated. Intestinal

discomfort, diarrhoea, and food intolerance especially have to be taken into account as long-term consequences that may impair patients' performance status and especially suitability for adjuvant therapies. However, when a radical resection can be performed, present data support this concept in young and otherwise healthy patients as, once the postoperative course is completed, the prognosis from the oncological point of view seems to be superior to any palliative treatment option. Future studies in growing patient collectives will add evidence to these topics.

6. Conclusions

In conclusion, vascular resections in PDAC surgery are extended approaches and can be performed in many situations. The recent ISGPS consensus definitions of borderline resectability and extended resections will help to standardize these procedures in the scientific reporting in the future and make studies on this topic more comparable. Venous resections should routinely be performed when there are no other contraindications for surgery in the respective patients and can also be combined with multivisceral approaches with good surgical and oncological outcome which has also been clearly stated in national and international guidelines in the meantime. Arterial resections might be justified in selected cases after careful evaluation of the risk-benefit ratio for the individual patient. In the majority of patients, however, an evident arterial infiltration should primarily be treated by neoadjuvant therapy and reevaluated for a possibility of surgery afterwards. All surgical approaches must be part of interdisciplinary multimodal concepts as radical resection alone cannot achieve optimal patient outcome and always needs to be followed by adjuvant treatment.

Conflict of Interests

The authors declare no conflict of interests regarding the paper.

References

- [1] R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," *CA Cancer Journal for Clinicians*, vol. 64, no. 1, pp. 9–29, 2014.
- [2] D. Hariharan, A. Saied, and H. M. Kocher, "Analysis of mortality rates for pancreatic cancer across the world," *HPB*, vol. 10, no. 1, pp. 58–62, 2008.
- [3] W. Hartwig, T. Hackert, U. Hinz et al., "Pancreatic cancer surgery in the new millennium: better prediction of outcome," *Annals of Surgery*, vol. 254, no. 2, pp. 311–319, 2011.
- [4] T. Schnelldorfer, A. L. Ware, M. G. Sarr et al., "Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma is cure possible?" *Annals of Surgery*, vol. 247, no. 3, pp. 456–462, 2008.
- [5] J. D. Birkmeyer, A. E. Siewers, E. V. A. Finlayson et al., "Hospital volume and surgical mortality in the United States," *The New England Journal of Medicine*, vol. 346, no. 15, pp. 1128–1137, 2002.
- [6] J. T. McPhee, J. S. Hill, G. F. Whalen et al., "Perioperative mortality for pancreatectomy: a national perspective," *Annals of Surgery*, vol. 246, no. 2, pp. 246–253, 2007.

- [7] T. Hackert, M. W. Büchler, and J. Werner, "Surgical options in the management of pancreatic cancer," *Minerva Chirurgica*, vol. 64, no. 5, pp. 465–476, 2009.
- [8] T. Hackert, C. Tjaden, and M. W. Büchler, "Developments in pancreatic surgery during the past ten years," *Zentralblatt für Chirurgie*, vol. 139, no. 3, pp. 292–300, 2014.
- [9] T. Seufferlein, M. Porzner, T. Becker et al., "S3-guideline exocrine pancreatic cancer," *Zeitschrift für Gastroenterologie*, vol. 51, no. 12, pp. 1395–1440, 2013.
- [10] T. Seufferlein, J. B. Bachet, E. van cutsem, and P. Rougier, "Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up," *Annals of Oncology*, vol. 23, supplement 7, pp. vii33–vii40, 2012.
- [11] M. Bockhorn, F. G. Uzunoglu, M. Adham et al., "Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)," *Surgery*, vol. 155, no. 6, pp. 977–988, 2014.
- [12] W. Hartwig, C. M. Vollmer, A. Fingerhut et al., "Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS)," *Surgery*, vol. 156, no. 1, pp. 1–14, 2014.
- [13] L. E. Harrison, D. S. Klimstra, and M. F. Brennan, "Isolated portal vein involvement in pancreatic adenocarcinoma: a contraindication for resection?" *Annals of Surgery*, vol. 224, no. 3, pp. 342–349, 1996.
- [14] M. Hartel, M. Niedergethmann, M. Farag-Soliman et al., "Benefit of venous resection for ductal adenocarcinoma of the pancreatic head," *European Journal of Surgery*, vol. 168, no. 12, pp. 707–712, 2002.
- [15] H. Riediger, F. Makowiec, E. Fischer, U. Adam, and U. T. Hopt, "Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection," *Journal of Gastrointestinal Surgery*, vol. 10, no. 8, pp. 1106–1115, 2006.
- [16] M. Ouaissi, C. Hubert, R. Verhelst et al., "Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure," *World Journal of Surgery*, vol. 34, no. 11, pp. 2648–2661, 2010.
- [17] V. M. Banz, D. Croagh, C. Coldham et al., "Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas," *European Journal of Surgical Oncology*, vol. 38, no. 1, pp. 72–79, 2012.
- [18] Y. Murakami, K. Uemura, T. Sudo et al., "Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma," *Journal of Surgical Oncology*, vol. 107, no. 4, pp. 414–421, 2013.
- [19] R. Ravikumar, C. Sabin, M. A. Hilal et al., "Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study," *Journal of the American College of Surgeons*, vol. 218, no. 3, pp. 401–411, 2014.
- [20] B. Kulemann, J. Hoepfner, U. Wittel et al., "Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer," *Journal of Gastrointestinal Surgery*, vol. 19, no. 3, pp. 438–444, 2015.
- [21] K. B. Stitzenberg, J. C. Watson, A. Roberts et al., "Survival after pancreatectomy with major arterial resection and reconstruction," *Annals of Surgical Oncology*, vol. 15, no. 5, pp. 1399–1406, 2008.
- [22] C. Wang, H. Wu, J. Xiong et al., "Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study," *Journal of Gastrointestinal Surgery*, vol. 12, no. 12, pp. 2183–2190, 2008.
- [23] Y. Sugiura, T. Horio, S. Aiko et al., "Pancreatectomy for pancreatic cancer with reference to combined resection of the vessels, twenty nine year experience by a single surgeon," *Keio Journal of Medicine*, vol. 58, no. 2, pp. 103–109, 2009.
- [24] W. Hartwig, T. Hackert, U. Hinz et al., "Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome," *Annals of Surgery*, vol. 250, no. 1, pp. 81–87, 2009.
- [25] Y. Yamamoto, Y. Sakamoto, D. Ban et al., "Is celiac axis resection justified for T4 pancreatic body cancer?" *Surgery*, vol. 151, no. 1, pp. 61–69, 2012.
- [26] H. Yoshidome, H. Shimizu, M. Ohtsuka et al., "Pancreaticoduodenectomy combined with hepatic artery resection following preoperative hepatic arterial embolization," *Journal of Hepato-Biliary-Pancreatic Sciences*, vol. 21, no. 12, pp. 850–855, 2014.
- [27] S. Bang, H. W. Chung, S. W. Park et al., "The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer," *Journal of Clinical Gastroenterology*, vol. 40, no. 10, pp. 923–929, 2006.
- [28] D. Habermehl, K. Kessel, T. Welzel et al., "Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer," *Radiation Oncology*, vol. 7, no. 1, article 28, 2012.
- [29] J. G. Fortner, "Regional resection of cancer of the pancreas: a new surgical approach," *Surgery*, vol. 73, no. 2, pp. 307–320, 1973.
- [30] J. Weitz, P. Kienle, J. Schmidt, H. Friess, and M. W. Büchler, "Portal vein resection for advanced pancreatic head cancer," *Journal of the American College of Surgeons*, vol. 204, no. 4, pp. 712–716, 2007.
- [31] A. R. Sasson, J. P. Hoffman, E. A. Ross et al., "En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?," *Journal of Gastrointestinal Surgery*, vol. 6, no. 2, pp. 147–158, 2002.
- [32] M. Shoup, K. C. Conlon, D. Klimstra, and M. F. Brennan, "Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?" *Journal of Gastrointestinal Surgery*, vol. 7, no. 8, pp. 946–952, 2003.
- [33] S. A. Müller, M. Hartel, A. Mehrabi et al., "Vascular resection in pancreatic cancer surgery: survival determinants," *Journal of Gastrointestinal Surgery*, vol. 13, no. 4, pp. 784–792, 2009.
- [34] P. T. W. Kim, A. C. Wei, E. G. Atenafu et al., "Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma," *British Journal of Surgery*, vol. 100, no. 10, pp. 1349–1356, 2013.
- [35] R. C. G. Martin II, C. R. Scoggins, V. Egnatashvili, C. A. Staley, K. M. McMasters, and D. A. Kooby, "Arterial and venous resection for pancreatic adenocarcinoma operative and long-term outcomes," *Archives of Surgery*, vol. 144, no. 2, pp. 154–159, 2009.
- [36] H. P. P. Siriwardana and A. K. Siriwardana, "Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer," *British Journal of Surgery*, vol. 93, no. 6, pp. 662–673, 2006.
- [37] Y. Zhou, Z. Zhang, Y. Liu, B. Li, and D. Xu, "Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis," *World Journal of Surgery*, vol. 36, no. 4, pp. 884–891, 2012.
- [38] T. Hackert, J. Weitz, and M. W. Büchler, "Reinsertion of the gastric coronary vein to avoid venous gastric congestion in pancreatic surgery," *HPB*, vol. 17, no. 4, pp. 368–370, 2015.

- [39] U. Settmacher, J. M. Langrehr, I. Husmann et al., "Reconstruction of visceral arteries with homografts in excision of the pancreas," *Chirurg*, vol. 75, no. 12, pp. 1199–1206, 2004.
- [40] E. F. Yekebas, D. Bogoevski, G. Cataldegirmen et al., "En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients," *Annals of Surgery*, vol. 247, no. 2, pp. 300–309, 2008.
- [41] B. Li, F.-Z. Chen, X.-H. Ge et al., "Pancreaticoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic head," *Hepatobiliary and Pancreatic Diseases International*, vol. 3, no. 4, pp. 612–615, 2004.
- [42] H. Amano, F. Miura, N. Toyota et al., "Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?" *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 16, no. 6, pp. 850–857, 2009.
- [43] J. Werner, S. E. Combs, C. Springfield, W. Hartwig, T. Hackert, and M. W. Büchler, "Advanced-stage pancreatic cancer: therapy options," *Nature Reviews Clinical Oncology*, vol. 10, no. 6, pp. 323–333, 2013.
- [44] O. Strobel, V. Berens, U. Hinz et al., "Resection after neoadjuvant therapy for locally advanced, 'unresectable' pancreatic cancer," *Surgery (United States)*, vol. 152, supplement 1, no. 3, pp. S33–S42, 2012.
- [45] J. D. Allendorf, M. Lauerman, A. Bill et al., "Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival," *Journal of Gastrointestinal Surgery*, vol. 12, no. 1, pp. 91–100, 2008.
- [46] T.-Y. Cheng, K. Sheth, R. R. White et al., "Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy," *Annals of Surgical Oncology*, vol. 13, no. 1, pp. 66–74, 2006.
- [47] P. Massucco, L. Capussotti, A. Magnino et al., "Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival," *Annals of Surgical Oncology*, vol. 13, no. 9, pp. 1201–1208, 2006.
- [48] J. Weitz, N. Rahbari, M. Koch, and M. W. Büchler, "The 'artery first' approach for resection of pancreatic head cancer," *Journal of the American College of Surgeons*, vol. 210, no. 2, pp. e1–e4, 2010.
- [49] N. Mollberg, N. N. Rahbari, M. Koch et al., "Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis," *Annals of Surgery*, vol. 254, no. 6, pp. 882–893, 2011.
- [50] J. B. Rose, F. Rocha, A. Alseidi, and S. Helton, "Posterior 'superior mesenteric artery first' approach for resection of locally advanced pancreatic cancer," *Annals of Surgical Oncology*, vol. 21, no. 6, pp. 1927–1928, 2014.
- [51] J. S. Gundara, F. Wang, R. Alvarado-Bachmann et al., "The clinical impact of early complete pancreatic head devascularisation during pancreatoduodenectomy," *The American Journal of Surgery*, vol. 206, no. 4, pp. 518–525, 2013.
- [52] Y. Inoue, A. Saiura, R. Yoshioka et al., "Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach," *Annals of Surgery*, 2015.
- [53] P. Sanjay, K. Takaori, S. Govil, S. V. Shrikhande, and J. A. Windsor, "Artery-first' approaches to pancreatoduodenectomy," *British Journal of Surgery*, vol. 99, no. 8, pp. 1027–1035, 2012.
- [54] S. V. Shrikhande, S. G. Barreto, Y. D. Bodhankar et al., "Superior mesenteric artery first combined with uncinate process approach versus uncinate process first approach in pancreatoduodenectomy: a comparative study evaluating perioperative outcomes," *Langenbeck's Archives of Surgery*, vol. 396, no. 8, pp. 1205–1212, 2011.
- [55] T. C. Chua and A. Saxena, "Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review," *Journal of Gastrointestinal Surgery*, vol. 14, no. 9, pp. 1442–1452, 2010.
- [56] M. Glanemann, B. Shi, F. Liang et al., "Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery?" *World Journal of Surgical Oncology*, vol. 6, article 123, 2008.
- [57] X. Wu, R. Tao, R. Lei et al., "Distal pancreatectomy combined with celiac axis resection in treatment of carcinoma of the body/tail of the pancreas: a single-center experience," *Annals of Surgical Oncology*, vol. 17, no. 5, pp. 1359–1366, 2010.
- [58] T. Hackert, J. Weitz, and M. W. Büchler, "Splenic artery use for arterial reconstruction in pancreatic surgery," *Langenbeck's Archives of Surgery*, vol. 399, no. 5, pp. 667–671, 2014.
- [59] S. Gaujoux, A. Sauvanet, M.-P. Vullierme et al., "Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management," *Annals of Surgery*, vol. 249, no. 1, pp. 111–117, 2009.
- [60] T. Hackert, U. Stampfl, H. Schulz, O. Strobel, M. W. Büchler, and J. Werner, "Clinical significance of liver ischaemia after pancreatic resection," *British Journal of Surgery*, vol. 98, no. 12, pp. 1760–1765, 2011.